Single-Arm, Open-Label, Phase II Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Phase of Trial: Phase II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs LY 3023414 (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 13 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 10 Mar 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.
- 18 Sep 2015 New trial record